Skip Navigation

Human Molecular Genetics 2005 14(Review Issue 1):R65-R76; doi:10.1093/hmg/ddi113
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Laird, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laird, P. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Cancer epigenetics

Peter W. Laird*

Departments of Surgery and of Biochemistry and Molecular Biology, University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Room 6418, 1441 Estlake Avenue, Los Angeles, CA 90089-9176, USA

* To whom correspondence should be addressed at: Tel: +1 323 8650650; Fax: +1 323 8650158; Email: plaird{at}usc.edu

Received January 21, 2005; Accepted February 24, 2005

The field of cancer epigenetics is evolving rapidly on several fronts. Advances in our understanding of chromatin structure, histone modification, transcriptional activity and DNA methylation have resulted in an increasingly integrated view of epigenetics. In response to these insights, epigenetic therapy is expanding to include combinations of histone deacetylase inhibitors and DNA methyltransferase inhibitors. Zebularine, an orally administerable DNA methyltransferase inhibitor, has been a very promising recent addition to our arsenal of potentially useful drugs for epigenetic therapy. Aberrant DNA methylation patterns provide three powerful diagnostic applications as classification markers, sensitive detection markers, and risk assessment markers. Classification studies continue to increase in marker complexity, now incorporating microarrays, high-throughput bisulfite genomic sequencing and mass spectrometry, as the field moves to human epigenome projects. Sensitive detection technology has expanded from primarily blood-based cancer detection to include applications on a wide diversity of sample sources and is now also making inroads as a molecular risk assessment tool.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
P. Kapoor-Vazirani, J. D. Kagey, D. R. Powell, and P. M. Vertino
Role of hMOF-Dependent Histone H4 Lysine 16 Acetylation in the Maintenance of TMS1/ASC Gene Activity
Cancer Res., August 15, 2008; 68(16): 6810 - 6821.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. J. Weisenberger, B. N. Trinh, M. Campan, S. Sharma, T. I. Long, S. Ananthnarayan, G. Liang, F. J. Esteva, G. N. Hortobagyi, F. McCormick, et al.
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight
Nucleic Acids Res., August 1, 2008; 36(14): 4689 - 4698.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
C. Bock, J. Walter, M. Paulsen, and T. Lengauer
Inter-individual variation of DNA methylation and its implications for large-scale epigenome mapping
Nucleic Acids Res., June 1, 2008; 36(10): e55 - e55.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
M. Hackenberg and R. Matthiesen
Annotation-Modules: a tool for finding significant combinations of multisource annotations for gene lists
Bioinformatics, June 1, 2008; 24(11): 1386 - 1393.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
P. Karpinski, D. Ramsey, Z. Grzebieniak, M. M. Sasiadek, and N. Blin
The CpG Island Methylator Phenotype Correlates with Long-Range Epigenetic Silencing in Colorectal Cancer
Mol. Cancer Res., April 1, 2008; 6(4): 585 - 591.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
A. R. Isles and L. S. Wilkinson
Epigenetics: what is it and why is it important to mental disease?
Br. Med. Bull., March 1, 2008; 85(1): 35 - 45.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
J. Rodriguez, L. Vives, M. Jorda, C. Morales, M. Munoz, E. Vendrell, and M. A. Peinado
Genome-wide tracking of unmethylated DNA Alu repeats in normal and cancer cells
Nucleic Acids Res., February 11, 2008; 36(3): 770 - 784.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
J. A. Dahl and P. Collas
{micro}ChIP--a rapid micro chromatin immunoprecipitation assay for small cell samples and biopsies
Nucleic Acids Res., February 11, 2008; 36(3): e15 - e15.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. V. Mishra, K. S. Bisht, L. Sun, K. Muldoon-Jacobs, R. Awwad, A. Kaushal, P. Nguyen, L. Huang, J. D. Pennington, S. Markovina, et al.
DNMT1 as a Molecular Target in a Multimodality-Resistant Phenotype in Tumor Cells
Mol. Cancer Res., February 1, 2008; 6(2): 243 - 249.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. Illi, C. D. Russo, C. Colussi, J. Rosati, M. Pallaoro, F. Spallotta, D. Rotili, S. Valente, G. Ragone, F. Martelli, et al.
Nitric Oxide Modulates Chromatin Folding in Human Endothelial Cells via Protein Phosphatase 2A Activation and Class II Histone Deacetylases Nuclear Shuttling
Circ. Res., January 4, 2008; 102(1): 51 - 58.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
S. Ogino and A. Goel
Molecular Classification and Correlates in Colorectal Cancer
J. Mol. Diagn., January 1, 2008; 10(1): 13 - 27.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
L. Fini, M. Selgrad, V. Fogliano, G. Graziani, M. Romano, E. Hotchkiss, Y. A. Daoud, E. B. De Vol, C. R. Boland, and L. Ricciardiello
Annurca Apple Polyphenols Have Potent Demethylating Activity and Can Reactivate Silenced Tumor Suppressor Genes in Colorectal Cancer Cells
J. Nutr., December 1, 2007; 137(12): 2622 - 2628.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
S. Ogino, T. Kawasaki, G. J Kirkner, Y. Suemoto, J. A Meyerhardt, and C. S Fuchs
Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer
Gut, November 1, 2007; 56(11): 1564 - 1571.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
M. R.H. Estecio, P. S. Yan, A. E.K. Ibrahim, C. S. Tellez, L. Shen, T. H.-M. Huang, and J.-P. J. Issa
High-throughput methylation profiling by MCA coupled to CpG island microarray
Genome Res., October 1, 2007; 17(10): 1529 - 1536.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
C. M Ulrich
Folate and cancer prevention: a closer look at a complex picture
Am. J. Clinical Nutrition, August 1, 2007; 86(2): 271 - 273.
[Full Text] [PDF]


Home page
J AndrolHome page
K. Biermann and K. Steger
Epigenetics in Male Germ Cells
J Androl, July 1, 2007; 28(4): 466 - 480.
[Full Text] [PDF]


Home page
JAMAHome page
C. M. Ulrich and J. D. Potter
Folate and Cancer--Timing Is Everything
JAMA, June 6, 2007; 297(21): 2408 - 2409.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, N. Shiraishi, Y. Okawa, H. Ikeda, S. Vallet, S. Pozzi, et al.
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Mol. Cancer Ther., June 1, 2007; 6(6): 1718 - 1727.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. Miremadi, M. Z. Oestergaard, P. D.P. Pharoah, and C. Caldas
Cancer genetics of epigenetic genes
Hum. Mol. Genet., April 15, 2007; 16(R1): R28 - R49.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
S. J. Clark
Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis
Hum. Mol. Genet., April 15, 2007; 16(R1): R88 - R95.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
R. Vibhakar, G. Foltz, J.-g. Yoon, L. Field, H. Lee, G.-y. Ryu, J. Pierson, B. Davidson, and A. Madan
Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma
Neuro-oncol, April 1, 2007; 9(2): 135 - 144.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
A. C. Boquest, A. Noer, A. L. Sorensen, K. Vekterud, and P. Collas
CpG Methylation Profiles of Endothelial Cell-Specific Gene Promoter Regions in Adipose Tissue Stem Cells Suggest Limited Differentiation Potential Toward the Endothelial Cell Lineage
Stem Cells, April 1, 2007; 25(4): 852 - 861.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
J. A. Dahl and P. Collas
Q2ChIP, a Quick and Quantitative Chromatin Immunoprecipitation Assay, Unravels Epigenetic Dynamics of Developmentally Regulated Genes in Human Carcinoma Cells
Stem Cells, April 1, 2007; 25(4): 1037 - 1046.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
R. Zhang, S.-t. Liu, W. Chen, M. Bonner, J. Pehrson, T. J. Yen, and P. D. Adams
HP1 Proteins Are Essential for a Dynamic Nuclear Response That Rescues the Function of Perturbed Heterochromatin in Primary Human Cells
Mol. Cell. Biol., February 1, 2007; 27(3): 949 - 962.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
M. Fang, D. Chen, and C. S. Yang
Dietary Polyphenols May Affect DNA Methylation
J. Nutr., January 1, 2007; 137(1): 223S - 228S.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J.-H. Lee, J.-H. Park, Y. Jung, J.-H. Kim, H.-S. Jong, T.-Y. Kim, and Y.-J. Bang
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
Mol. Cancer Ther., December 1, 2006; 5(12): 3085 - 3095.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
N. C. Whitelaw and E. Whitelaw
How lifetimes shape epigenotype within and across generations
Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R131 - R137.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. Young and J. R. Jass
The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1778 - 1784.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Dominguez
Interplay between Notch Signaling and Epigenetic Silencers in Cancer.
Cancer Res., September 15, 2006; 66(18): 8931 - 8934.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
X. Qian, W. J. LaRochelle, G. Ara, F. Wu, K. D. Petersen, A. Thougaard, M. Sehested, H. S. Lichenstein, and M. Jeffers
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.
Mol. Cancer Ther., August 1, 2006; 5(8): 2086 - 2095.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
A. Noer, A. L. Sorensen, A. C. Boquest, and P. Collas
Stable CpG Hypomethylation of Adipogenic Promoters in Freshly Isolated, Cultured, and Differentiated Mesenchymal Stem Cells from Adipose Tissue
Mol. Biol. Cell, August 1, 2006; 17(8): 3543 - 3556.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Foltz, G.-Y. Ryu, J.-G. Yoon, T. Nelson, J. Fahey, A. Frakes, H. Lee, L. Field, K. Zander, Z. Sibenaller, et al.
Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma.
Cancer Res., July 1, 2006; 66(13): 6665 - 6674.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
S Ogino, M Cantor, T Kawasaki, M Brahmandam, G J Kirkner, D J Weisenberger, M Campan, P W Laird, M Loda, and C S Fuchs
CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies
Gut, July 1, 2006; 55(7): 1000 - 1006.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. K. Leung, E. P.S. Man, J. Yu, M. Y.Y. Go, K.-f. To, Y. Yamaoka, V. Y.Y. Cheng, E. K.W. Ng, and J. J.Y. Sung
Effects of Helicobacter pylori Eradication on Methylation Status of E-Cadherin Gene in Noncancerous Stomach.
Clin. Cancer Res., May 15, 2006; 12(10): 3216 - 3221.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
R. D. Hawkins and B. Ren
Genome-wide location analysis: insights on transcriptional regulation.
Hum. Mol. Genet., April 15, 2006; 15(suppl_1): R1 - R7.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Yuan, F. Haghighi, S. White, R. Costa, J. McMinn, K. Chun, M. Minden, and B. Tycko
A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons.
Cancer Res., April 1, 2006; 66(7): 3443 - 3451.
[Abstract] [Full Text] [PDF]


Home page
Int J EpidemiolHome page
J. PEEDICAYIL
Genes underlying common complex diseases
Int. J. Epidemiol., April 1, 2006; 35(2): 490 - 491.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. K. Vanaja, K. V. Ballman, B. W. Morlan, J. C. Cheville, R. M. Neumann, M. M. Lieber, D. J. Tindall, and C. Y.F. Young
PDLIM4 Repression by Hypermethylation as a Potential Biomarker for Prostate Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1128 - 1136.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Herranz, J. Martin-Caballero, M. F. Fraga, J. Ruiz-Cabello, J. M. Flores, M. Desco, V. Marquez, and M. Esteller
The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma
Blood, February 1, 2006; 107(3): 1174 - 1177.
[Abstract] [Full Text] [PDF]


Home page
DNA ResHome page
J. Cheong, Y. Yamada, R. Yamashita, T. Irie, A. Kanai, H. Wakaguri, K. Nakai, T. Ito, I. Saito, S. Sugano, et al.
Diverse DNA Methylation Statuses at Alternative Promoters of Human Genes in Various Tissues
DNA Res, January 1, 2006; 13(4): 155 - 167.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. J. Noh, E. R. Jang, G. Jeong, Y. M. Lee, C. K. Min, and J.-S. Lee
Methyl CpG-Binding Domain Protein 3 Mediates Cancer-Selective Cytotoxicity by Histone Deacetylase Inhibitors via Differential Transcriptional Reprogramming in Lung Cancer Cells
Cancer Res., December 15, 2005; 65(24): 11400 - 11410.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
R. K. Neely, D. Daujotyte, S. Grazulis, S. W. Magennis, D. T. F. Dryden, S. Klimasauskas, and A. C. Jones
Time-resolved fluorescence of 2-aminopurine as a probe of base flipping in M.HhaI-DNA complexes
Nucleic Acids Res., December 9, 2005; 33(22): 6953 - 6960.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Ulrich, K. Curtin, J. D. Potter, J. Bigler, B. Caan, and M. L. Slattery
Polymorphisms in the Reduced Folate Carrier, Thymidylate Synthase, or Methionine Synthase and Risk of Colon Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2509 - 2516.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
W. Sadee and Z. Dai
Pharmacogenetics/genomics and personalized medicine
Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R207 - R214.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.